Days Sales in Receivables: The average number of days it takes to collect outstanding receivable amounts from customers. Calculated as: Number of Days in Period / Receivable Turnover
Supernus Pharmaceuticals, Inc. (SUPN) had Days Sales in Receivables of 78.94 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$207.71M |
|
$-2.29M |
|
$23.39M |
|
$184.31M |
|
$216.04M |
|
$-8.33M |
|
$2.38M |
|
$-5.95M |
|
$-5.95M |
|
$-2.29M |
|
$-2.29M |
|
$-2.29M |
|
$-2.29M |
|
$-8.33M |
|
$17.61M |
|
57.65M |
|
57.65M |
|
$-0.04 |
|
$-0.04 |
|
| Balance Sheet Financials | |
$731.58M |
|
$10.04M |
|
$769.14M |
|
$1.50B |
|
$373.93M |
|
-- |
|
$49.99M |
|
$423.92M |
|
$1.08B |
|
$406.42M |
|
$1.08B |
|
58.04M |
|
| Cash Flow Statement Financials | |
$66.52M |
|
$-19.22M |
|
$9.12M |
|
$129.90M |
|
$186.32M |
|
$56.42M |
|
$8.48M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.96 |
|
-- |
|
-- |
|
-- |
|
-- |
|
88.74% |
|
-4.01% |
|
-4.01% |
|
-- |
|
-2.86% |
|
-1.10% |
|
$66.52M |
|
-- |
|
-- |
|
-- |
|
0.14 |
|
0.27 |
|
1.14 |
|
|
Days Sales in Receivables |
78.94 |
-0.21% |
|
-0.56% |
|
-0.15% |
|
-0.21% |
|
$18.55 |
|
$1.15 |
|
$1.15 |
|